Market revenue in 2023 | USD 216.5 million |
Market revenue in 2030 | USD 321.9 million |
Growth rate | 5.8% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Abbott Laboratories, Thermo Fisher Scientific Inc, Roche Holding AG ADR, Qiagen NV, Siemens Healthineers AG ADR, Becton Dickinson & Co, Illumina Inc, Epigenomics AG, Koninklijke Philips NV, FUJIFILM Holdings Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liver cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 60.92% in 2023. Horizon Databook has segmented the Japan liver cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Rise in initiatives undertaken by the government is expected to boost the market growth in the near future. Liver cancer screening was established in the 1980s in Japan involving most of the institutes in the country. Liver cancer screening is mostly done by ultrasound and also by measuring of three tumor markers that include AFP, AFP-L3, and PIVKA-II.
These tests are mostly recommended within 3-4 months for patients who are at high-risk of cirrhosis caused by hepatitis B or C virus. Furthermore, an additional screening is recommended within 6 months for patients who at high-risk of hepatitis B, hepatitis C, & nonviral cirrhosis.
Also, for patients who are at super high-risk, multidetector-row computed tomography or MDCT or gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid magnetic resonance imaging or EOB-MRI is recommended around 1-2 times per year.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan liver cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Japan liver cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account